A phase II study of Triapine (NSC 663249) [OCX 0191] in previously untreated patients with recurrent renal cell carcinoma.
Phase of Trial: Phase II
Latest Information Update: 28 Mar 2016
At a glance
- Drugs OCX 191 (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- 21 Sep 2013 Additional lead trial centre added as reported by ClinicalTrials.gov.
- 10 Sep 2005 New trial record.